Which medication is commonly given to dialysis patients to manage anemia?

Erythropoiesis-stimulating agents (ESAs) are commonly administered to dialysis patients to manage anemia, particularly because kidney disease often leads to decreased production of erythropoietin, a hormone that stimulates red blood cell production in the bone marrow. Patients with chronic kidney disease often experience anemia due to reduced erythropoietin levels, making ESAs an effective treatment option to stimulate red blood cell production and improve hemoglobin levels.

While iron supplements, B12 injections, and folic acid may play supportive roles in the management of anemia, particularly in addressing deficiencies, ESAs directly target the underlying issue of insufficient erythropoietin in these patients. Therefore, using ESAs is essential for managing anemia effectively in the context of dialysis treatment.